<!DOCTYPE html>
<html>
<head>
	<title>MRCG Clinical Guidelines</title>
	<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=2.0, user-scalable=1">
	<meta name=Generator content="Microsoft Word 14 (filtered)">
	<link rel="stylesheet" href="jquery.mobile-1.4.5.min.css" />
	<script src="jquery-1.11.1.min.js"></script>
	<script src="jquery.mobile-1.4.5.min.js"></script>
	<script type="text/javascript" src="cordova.js"></script>      
	<style>
	.show {display: block;}
	.tablist-left {
    width: 25%;
    display: inline-block;
  }
  .tablist-content {
    width: 60%;
    display: inline-block;
    vertical-align: top;
    margin-left: 5%;
    }
    body {
  font-family: Arial, Helvetica, sans-serif;
  font-size: 20px;
}
.footer-button-left,
.footer-button-right {
    position: absolute;
    margin: 0;
    top: auto;
    bottom: 0.24em;
}
.footer-button-left {
    left: 0.4em;
}
.footer-button-right {
    right: 0.4em;
}
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Lucida Grande";}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:OpenSymbol;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:18.0pt;
	margin-left:0cm;
	font-size:14.0pt;
	font-family:"Arial","sans-serif";}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:12.0pt;
	margin-left:0cm;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:9.0pt;
	margin-left:36.0pt;
	text-indent:-36.0pt;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";
	text-decoration:underline;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:2.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	color:#365F91;
	font-weight:normal;
	font-style:italic;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:7.0pt;
	margin-left:0cm;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Cambria","serif";}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:9.0pt;
	font-family:"Lucida Grande","sans-serif";}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Arial","sans-serif";
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Arial","sans-serif";
	font-weight:bold;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Lucida Grande","sans-serif";}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Arial","sans-serif";
	font-weight:bold;
	text-decoration:underline;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Arial","sans-serif";}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Calibri","sans-serif";
	color:#365F91;
	font-style:italic;}
span.UnresolvedMention
	{mso-style-name:"Unresolved Mention";
	color:#605E5C;
	background:#E1DFDD;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Cambria","serif";}
span.InternetLink
	{mso-style-name:"Internet Link";
	color:#047AC6;
	text-decoration:underline;}
.MsoChpDefault
	{font-size:10.0pt;
	font-family:"Tahoma","sans-serif";}
 /* Page Definitions */
 @page WordSection1
	{size:612.0pt 792.0pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
 .tableCont {
    overflow: auto;
    -webkit-overflow-scrolling: touch;
}
  </style>
  	<script>
		$(function(){
			$( "[data-role='header'], [data-role='footer']" ).toolbar();
			$('input[data-type="search"]').val("");			
		});
		// When the user scrolls down 20px from the top of the document, show the button
		window.onscroll = function() {scrollFunction()};
		function scrollFunction() {
		  if (document.body.scrollTop > 20 || document.documentElement.scrollTop > 20) {
			document.getElementById("myBtn").style.display = "block";
		  } else {
			document.getElementById("myBtn").style.display = "none";
		  }
		}
		// When the user clicks on the button, scroll to the top of the document
		function topFunction() {
		  document.body.scrollTop = 0; // For Safari
		  document.documentElement.scrollTop = 0; // For Chrome, Firefox, IE and Opera
		}
	</script>

</head>
<body lang=EN-GB link=blue vlink=purple>
	<div data-role="header" data-tap-toggle="false" data-id="persistent-header" data-position="fixed" data-theme="a">
		<h2 style="font-size:0.75em;">MRCG<br>Clinical Guidelines<br></h2>
		<a data-rel="back" class="ui-btn ui-corner-all ui-btn-inline ui-mini header-button-left ui-btn-icon-left ui-icon-carat-l">Back</a>
<a href="#leftpanel1" class="ui-btn ui-shadow ui-corner-all ui-btn-inline ui-mini header-button-left ui-icon-info ui-btn-icon-notext">About this app</a>
		<a href="#popupNested"  data-rel="popup" class="ui-btn ui-corner-all ui-shadow ui-btn-inline ui-icon-bars ui-btn-icon-right ui-btn-b header-button-right" data-transition="pop">Choose a guideline...</a>
		<div data-role="popup" id="popupNested" data-theme="a"><ul data-role="listview" data-filter="true"data-filter-placeholder="Type to search names..." data-inset="true">
			<li><a href="Acute_kidney_injury_MeG-CLS-071.html">Acute kidney injury</a></li>
			<li><a href="Acute_rheumatic_fever__MeG-CLS-048.html">Acute rheumatic fever </a></li>
			<li><a href="Animal_bites_MeG-CLS-049.html">Animal bites</a></li>
			<li><a href="Asthma_MeG-CLS-001.html">Asthma</a></li>
			<li><a href="Bone_and_joint_infections_guidelines_MeG-CLS-050.html">Bone and joint infections guidelines</a></li>
			<li><a href="Cellulitis_MeG-CLS-051.html">Cellulitis</a></li>
			<li><a href="Chest_pain_and_Acute_Coronary_Syndrome_MeG-CLS-052.html">Chest pain and Acute Coronary Syndrome</a></li>
			<li><a href="Chronic_kidney_disease_MeG-CLS-053.html">Chronic kidney disease</a></li>
			<li><a href="Congenital_heart_disease_MeG-CLS-039.html">Congenital heart disease</a></li>
			<li><a href="Constipation_MeG-CLS-003.html">Constipation</a></li>
			<li><a href="COPD_MeG-CLS-032.html">Chronic Obstructive Pulmonary Disease</a></li>
			<li><a href="Croup_MeG-CLS-059.html">Croup</a></li>
			<li><a href="Deep_venous_thombosis_and_pulmonary_embolism_MeG-CLS-055.html">Deep venous thombosis and pulmonary embolism</a></li>
			<li><a href="Depression_MeG-CLS-075.html">Depression</a></li>
			<li><a href="Developmental_delay_MeG-CLS-054.html">Developmental delay</a></li>
			<li><a href="Diabetes_Mellitus_MeG-CLS-004.html">Diabetes Mellitus</a></li>
			<li><a href="DKA_MeG-CLS-021.html">Diabetic ketoacidosis</a></li>
			<li><a href="Dyspepsia_MeG-CLS-034.html">Dyspepsia</a></li>
			<li><a href="Ear_pain_MeG-CLS-070.html">Ear pain</a></li>
			<li><a href="Epiglottitis_MeG-CLS-063.html">Epiglottitis</a></li>
			<li><a href="Epilepsy_MeG-CLS-056.html">Epilepsy</a></li>
			<li><a href="Fungal_Skin_Infections_MeG-CLS-057.html">Fungal Skin Infections</a></li>
			<li><a href="Gastroenteritis_MeG-CLS-033.html">Gastroenteritis</a></li>
			<li><a href="General_Body_Pain_MeG-CLS-007.html">General Body Pain</a></li>
			<li><a href="Headache_MeG-CLS-045.html">Headache</a></li>
			<li><a href="Heart_failure_adults_MeG-CLS-040.html">Heart failure adults</a></li>
			<li><a href="HHS_MeG-CLS-046.html">Hyperosmolar Hyperglycaemic State</a></li>
			<li><a href="HIV_MeG-CLS-035.html">HIV</a></li>
			<li><a href="Hypertension_MeG-CLS-010.html">Hypertension</a></li>
			<li><a href="Hyperthyroidism_and_goitre_MeG-CLS-027.html">Hyperthyroidism and goitre</a></li>
			<li><a href="Hypocalcaemia_and_hypercalcaemia_MeG-CLS-074.html">Hypocalcaemia and hypercalcaemia</a></li>
			<li><a href="Hypokalaemia_hyperkalaemia_hypermagnesaemia_MeG-CLS-073.html">Hypokalaemia, hyperkalaemia, hypermagnesaemia</a></li>
			<li><a href="Hyponatraemia_and_hypernatraemia_MeG-CLS-072.html">Hyponatraemia and hypernatraemia</a></li>
			<li><a href="Hypothyroidism_MeG-CLS-036.html">Hypothyroidism</a></li>
			<li><a href="Infective_Endocarditis_MeG-CLS-058.html">Infective Endocarditis</a></li>
			<li><a href="Inflammatory_arthritis_and_connective_tissue_disease_MeG-CLS-041.html">Inflammatory arthritis and connective tissue disease</a></li>
			<li><a href="Intestinal_helminths_MeG-CLS-009.html">Intestinal helminths</a></li>
			<li><a href="Liver_disease_MeG-CLS-031.html">Liver disease</a></li>
			<li><a href="Lower_back_pain_MeG-CLS-022.html">Lower back pain</a></li>
			<li><a href="LRI_MeG-CLS-011.html">Lower Respiratory Infections</a></li>
			<li><a href="Malaria_MeG-CLS-012.html">Malaria</a></li>
			<li><a href="Malnutrition_MeG-CLS-037.html">Malnutrition</a></li>
			<li><a href="Meningitis_MeG-CLS-028.html">Meningitis</a></li>
			<li><a href="Neonatal_jaundice_MeG-CLS-060.html">Neonatal jaundice</a></li>
			<li><a href="Nephrotic_Syndrome_MeG-CLS-061.html">Nephrotic Syndrome</a></li>
			<li><a href="Osteoarthritis_MeG-CLS-042.html">Osteoarthritis</a></li>
			<li><a href="Otitis_media_MeG-CLS-023.html">Otitis media</a></li>
			<li><a href="Palliative_Care_MeG-CLS-064.html">Palliative Care</a></li>
			<li><a href="Rectal_prolapse_MeG-CLS-015.html">Rectal prolapse</a></li>
			<li><a href="Rheumatic_heart_disease_MeG-CLS-065.html">Rheumatic heart disease</a></li>
			<li><a href="Scabies_MeG-CLS-066.html">Scabies</a></li>
			<li><a href="Sepsis_in_adults_MeG-CLS-043.html">Sepsis in adults</a></li>
			<li><a href="Sinusitis_MeG-CLS-062.html">Sinusitis</a></li>
			<li><a href="Stevens-Johnsons_syndrome_MeG-CLS-067.html">Stevens-Johnsons syndrome</a></li>
			<li><a href="STI_MeG-CLS-038.html">Sexually Transmitted Infections</a></li>
			<li><a href="Stroke_MeG-CLS-020.html">Stroke</a></li>
			<li><a href="TB_MeG-CLS-044.html">TB</a></li>
			<li><a href="Tonsillitis_and_pharyngitis_MeG-CLS-024.html">Tonsillitis and pharyngitis</a></li>
			<li><a href="Trauma_MeG-CLS-068.html">Trauma</a></li>
			<li><a href="Upper_respiratory_tract_infections_MeG-CLS-018.html">Upper respiratory tract infections</a></li>
			<li><a href="UTI_MeG-CLS-019.html">Urinary tract infections</a></li>
</ul>
	  </div>
	  </div>
	 
    </div><!-- /header -->
<div data-role="page">
	<div role="main" class="ui-content">
<div class=WordSection1>
<h1><span lang=EN-US>Chronic kidney disease</span></h1>
<h2><i><span lang=EN-US>Executive summary</span></i></h2>
<h2><span lang=EN-US>Introduction</span></h2>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
lang=EN-US style='color:black'>Chronic kidney disease (CKD) is a process that
may progress over years and the end point of this process is renal failure.
Early detection and management of CKD improves mortality, and morbidity and delays
the point where dialysis is necessary which incur significant cost to the patient
in terms of life expectancy, quality of life and finances. Most patients with
CKD have a stable glomerular filtration rate (GFR), but an important minority
deteriorate to end stage kidney failure. The early stage of CKD is usually
asymptomatic, therefore must be detected by opportunistic testing of at-risk
groups or acting on incidental findings. Preventive measures may be taken to
slow the progression and minimise nephrotoxicity.</span></p>
<h2><span lang=EN-US>Target users</span></h2>
<p class=MsoListParagraphCxSpFirst style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Doctors</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Nurses</span></p>
<h2><span lang=EN-US>Target area of use </span></h2>
<p class=MsoListParagraphCxSpFirst style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Outpatients</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Ward</span></p>
<h2><span lang=EN-US>Key areas of focus / New additions / Changes </span></h2>
<p class=MsoNormal style='margin-top:12.0pt;margin-right:0cm;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt'><span lang=EN-US style='color:black'>This
guideline aims to address both management of the patient in chronic kidney
failure, and the early detection of CKD and minimising modifiable risks for
progression. </span></p>
<p class=MsoNormal style='margin-top:12.0pt;margin-right:0cm;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt'><span lang=EN-US style='color:black'>Conservative
management can be provided in accordance with the patient and with consulting
the palliative care guidelines for additional advice.</span></p>
<h3><span lang=EN-US>Aims for CSD</span></h3>
<p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Identification of patients
at risk of CKD.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Classification of patients
according to estimated GFR (or eGFR) with serum creatinine.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Urine reagent strip
(dipstick) analysis for broad quantification of kidney damage.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Monitoring progression of
CKD.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Optimisation
of&nbsp;pharmacotherapy and hypertension management.</span></p>
<p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Early referral to
nephrologists (at stage G4 or G3a with 3+ of protein on urine dipstick
analysis)</span></p>
<h2><span lang=EN-US>Limitations</span></h2>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
lang=EN-US style='color:black'>We cannot offer Renal Replacement Therapy (RRT)
and patients must be referred to the EFSTH hospital early, in anticipation of
deteriorating renal function, and at end stage renal failure. </span><span
lang=EN-US><br clear=all style='page-break-before:always'>
</span></p>
<h2><span lang=EN-US>Presenting symptoms and signs</span></h2>
<p class=MsoNormal><span lang=EN-US>Chronic kidney disease is asymptomatic in
most patients until end-stage renal failure occurs.</span></p>
<h2><span lang=EN-US>Examination findings</span></h2>
<p class=MsoBodyText style='line-height:normal'><span style='font-family:"Arial","sans-serif";
color:black'>Signs and symptoms of (end stage) kidney failure:</span></p>
<p class=MsoBodyText style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal'><span
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Arial","sans-serif";color:black'>Acid-base
or electrolyte abnormalities</span></p>
<p class=MsoBodyText style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal'><span
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Arial","sans-serif";color:black'>Pruritis</span></p>
<p class=MsoBodyText style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal'><span
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Arial","sans-serif";color:black'>Serositis
(pericarditis, pleuritis)</span></p>
<p class=MsoBodyText style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal'><span
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Arial","sans-serif";color:black'>Inability
to control volume status or blood pressure (severe hypertension, pulmonary
oedema)</span></p>
<p class=MsoBodyText style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal'><span
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Arial","sans-serif";color:black'>Progressive
deterioration in nutritional status refractory to dietary intervention</span></p>
<p class=MsoBodyText style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal'><span
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Arial","sans-serif";color:black'>Cognitive
impairment</span></p>
<p class=MsoBodyText style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal'><span
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Arial","sans-serif";color:black'>Anaemia</span></p>
<p class=MsoBodyText style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal'><span
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Arial","sans-serif";color:black'>Bone
pains</span></p>
<p class=MsoBodyText style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal'><span
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Arial","sans-serif";color:black'>Gastritis</span></p>
<h2><span lang=EN-US>Management </span></h2>
<h3><span lang=EN-US>Define ‘at risk’ patient groups:</span></h3>
<p class=MsoNormal><span lang=EN-US>Patients with the following conditions
should be screened for chronic kidney disease with serum creatinine and urine
dipstick:</span></p>
<p class=MsoListParagraphCxSpFirst style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Hypertension </span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Diabetes mellitus </span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Cardiovascular disease </span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Heart failure </span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Peripheral vascular disease </span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Ischaemic heart disease</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Cerebral vascular disease</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Acute kidney injury</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Family history of kidney disease</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Incidental findings of haematuria</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Multisystem disease that involves the kidney
(e.g. SLE). </span></p>
<p class=MsoNormal><span lang=EN-US>Current evidence does not support the
screening of unselected populations.</span></p>
<h2 style='margin-top:0cm;line-height:18.85pt'><span lang=EN-US>Investigations</span></h2>
<h3><span lang=EN-US>Serum Urea, Electrolytes and Creatinine:</span></h3>
<p class=MsoNormal><span lang=EN-US>Serum creatinine levels are useful for
estimating glomerular filtration rate. The CKD-EPI calculation gives better
estimations in the early stages of CKD. There are reliable online calculators
available e.g. <a
href="https://www.mdcalc.com/ckd-epi-equations-glomerular-filtration-rate-gfr"><span
style='color:black'>https://www.mdcalc.com/ckd-epi-equations-glomerular-filtration-rate-gfr</span></a></span></p>
<p class=MsoNormal><span lang=EN-US>CKD is classified into 5 stages. Stages 1
and 2 are defined by good GFR, but with markers of kidney damage e.g.
albuminuria, abnormalities in urine sediment, histological abnormalities,
structural abnormalities detected by imaging, history of kidney transplant, and
electrolyte disorders that are due to tubular disorders.</span></p>
<p class=MsoNormal><span lang=EN-US>Stages 3a, 3b, 4 and 5 are defined by GFR
of less than 60 ml/min/1.73m<sup>2</sup> with or without the evidence of kidney
damage. </span></p>
<p class=MsoNormal><span lang=EN-US>This diagnosis must be made from at least 3
instances of investigations with at least 90 days between the first and last
tests.</span></p>
<div class="tableCont">
  <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=601
 style='width:450.5pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=601 colspan=3 valign=top style='width:450.5pt;border:none;
  border-bottom:inset black 1.0pt;padding:2.4pt 24.0pt 2.4pt -1.1pt'><b><u><span
  lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
  clear=all style='page-break-before:always'>
  </span></u></b>
  <h3><span lang=EN-US>GFR categories</span></h3>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.25pt;border:inset black 1.0pt;
  border-top:none;padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-US>GFR category</span></b></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-US>GFR (ml/min/1.73&nbsp;m<sup>2</sup>)</span></b></p>
  </td>
  <td width=270 valign=top style='width:202.4pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-US>Terms</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.25pt;border:inset black 1.0pt;
  border-top:none;padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>G1</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>&gt;90</span></p>
  </td>
  <td width=270 valign=top style='width:202.4pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>Normal or high</span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.25pt;border:inset black 1.0pt;
  border-top:none;padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>G2</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>60–89</span></p>
  </td>
  <td width=270 valign=top style='width:202.4pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>Mildly decreased</span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.25pt;border:inset black 1.0pt;
  border-top:none;padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>G3a</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>45–59</span></p>
  </td>
  <td width=270 valign=top style='width:202.4pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>Mildly to moderately decreased</span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.25pt;border:inset black 1.0pt;
  border-top:none;padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>G3b</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>30–44</span></p>
  </td>
  <td width=270 valign=top style='width:202.4pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>Moderately to severely decreased</span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.25pt;border:inset black 1.0pt;
  border-top:none;padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>G4</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>15–29</span></p>
  </td>
  <td width=270 valign=top style='width:202.4pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>Severely decreased (<b>R</b>)</span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.25pt;border:inset black 1.0pt;
  border-top:none;padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>G5</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>&lt;15</span></p>
  </td>
  <td width=270 valign=top style='width:202.4pt;border-top:none;border-left:
  none;border-bottom:inset black 1.0pt;border-right:inset black 1.0pt;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center'><span lang=EN-US>Kidney failure (<b>R</b>)</span></p>
  </td>
 </tr>
 <tr>
  <td width=601 colspan=3 valign=top style='width:450.5pt;border:none;
  padding:2.4pt 24.0pt 2.4pt -1.1pt'>
  <p class=MsoNormal><span lang=EN-US>Abbreviations: CKD, chronic kidney
  disease; GFR, glomerular filtration rate, <b>R</b>- refer to EFSTH</span></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span lang=EN-US>Progression of CKD is the sustained
decrease in GFR of 25% or more with a change in GFR category within 12 months, <b>or
</b>a sustained decrease in GFR of 15 ml/min/1.73 m<sup>2</sup> per year.</span></p>
<h3><span lang=EN-US>Dipstick Urinalysis</span></h3>
<p class=MsoListParagraphCxSpFirst style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-US>Proteinuria</span></b><span lang=EN-US>: Test
for proteinuria in patients in the at-risk groups, and patients with abnormal
serum creatinine. Urine dipstick testing should occur at each appointment in
patients in groups G3a –G5 (eGFR &lt; 60 ml/min). Although urine
albumin-creatinine ratio is the ideal test for proteinuria, dipstick testing of
random urine samples is most practical for the OPD.</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-US>Haematuria</span></b><span lang=EN-US>: The
presence of 1+ or more of blood in urine is considered significant and should
be investigated further. Urine microscopy is not required to test or confirm
diagnosis. Invisible haematuria is confirmed with 2 out of 3 positive urine
analysis dipstick tests in separate clinic appointments. Investigate patients
with persistent invisible haematuria for urinary tract malignancy in the
appropriate age groups. Patients with invisible haematuria with proteinuria
should be followed up with annual repeat testing for as long as the haematuria
continues</span></p>
<h3><span lang=EN-US>Haemoglobin</span></h3>
<p class=MsoNormal><span lang=EN-US style='color:black'>Check the haemoglobin
level in people with a GFR of less than 45 ml/min/1.73 m<sup>2</sup> to
identify anaemia (haemoglobin less than 11 g/dl).</span></p>
<h3><span lang=EN-US>Serum calcium and phosphate</span></h3>
<p class=MsoNormal><span lang=EN-US style='color:black'>Low calcium and high
phosphate levels may be seen in patients in end stage renal disease.</span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><u><span
lang=EN-US><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>
<h3><span lang=EN-US>Renal ultrasound</span></h3>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
lang=EN-US style='color:black'>Perform renal ultrasound if there is:</span></p>
<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='color:black;margin-bottom:0cm;margin-bottom:.0001pt'><span
     lang=EN-US>accelerated progression of CKD</span></li>
 <li class=MsoNormal style='color:black;margin-bottom:0cm;margin-bottom:.0001pt'><span
     lang=EN-US>Haematuria or persisting invisible haematuria</span></li>
 <li class=MsoNormal style='color:black;margin-bottom:0cm;margin-bottom:.0001pt'><span
     lang=EN-US>Urinary tract obstruction</span></li>
 <li class=MsoNormal style='color:black;margin-bottom:0cm;margin-bottom:.0001pt'><span
     lang=EN-US>Family history of polycystic kidney disease </span></li>
 <li class=MsoNormal style='color:black;margin-bottom:0cm;margin-bottom:.0001pt'><span
     lang=EN-US>GFR of &lt;30 ml/min/1.73m<sup>2</sup> (G4 or G5)</span></li>
</ul>
<h2 style='margin-top:0cm;line-height:18.85pt'><span lang=EN-US>Treatment</span></h2>
<p class=MsoNormal><span lang=EN-US>At all stages, it is important to involve
the patient in shared decision making, discussing the implications of diagnosis
and prognosis, as well as preference for invasive treatment or conservative
management</span></p>
<h3><span lang=EN-US>Hypertension</span></h3>
<p class=MsoNormal><span lang=EN-US>Control systolic blood pressure in the
target range of 120 - 139 mmHg and keep diastolic blood pressure below 90 mmHg.
In those with diabetes, aim for tighter blood pressure control with target
systolic BP of 120 – 130 mmHg and diastolic BP of &lt; 80 mmHg. Refer to the
CSD hypertension guideline for more information on controlling blood pressure.</span></p>
<p class=MsoListParagraphCxSpFirst style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Single renin - angiotensin system antagonists
may be used (do not combine renin - angiotensin system antagonists): these
include ACE inhibitors and spironolactone.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Monitor potassium levels and withhold treatment
if Potassium &gt;6 mmol/l. </span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Check GFR when starting or increasing dose of
renin - angiotensin system antagonist. A deterioration of less than 25% is
acceptable. If the eGFR change is 25% or more, or the change in serum
creatinine is 30% or more, investigate other causes of deterioration in renal
function, such as volume depletion or concurrent medication (for example,
NSAIDs).If no other cause for the deterioration in renal function is found,
stop the renin–angiotensin system antagonist or reduce the dose to a previously
tolerated lower dose, and add an alternative antihypertensive medication if
required.</span></p>
<h3><span lang=EN-US>Reduce nephrotoxic medication burden:</span></h3>
<p class=MsoNormal><span lang=EN-US>Avoid giving the following drugs if
possible:</span></p>
<p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Antimicrobials: Vancomycin,
Quinolones, Aminoglycosides</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>NSAIDS, Methotrexate</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>ACE- Inhibitors, Angiotensin
Receptor Blocker, Renin Inhibitor</span></p>
<p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Statins - Offer atorvastatin
20 mg for the primary or secondary prevention of CVD to people with CKD.
Increase the dose if less than 40% reduction in non‑HDL cholesterol is achieved
and eGFR is 30 ml/min/1.73 m<sup>2</sup> or more. Do not give in patients with
eGFR &lt; 30 ml/min/1.73 m<sup>2</sup>.</span></p>
<h3><span lang=EN-US>Lifestyle advice:</span></h3>
<p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Encourage exercise, aim for
healthy weight, stop smoking.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Dietary advice regarding
calorie, salt, potassium and phosphate levels appropriate to the severity of
CKD.</span></p>
<p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='color:black'>Low protein diet should <b>not</b>
be recommended.</span></p>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
lang=EN-US style='color:black'>&nbsp;</span></p>
<h3><span lang=EN-US>Acute Kidney Injury (AKI):</span></h3>
<p class=MsoNormal><span lang=EN-US>Patients with CKD are more likely to
develop AKI than the normal population. AKI may also lead to progression of CKD</span></p>
<p class=MsoNormal><span lang=EN-US>AKI in the background of CKD should not be
managed with diuretics </span></p>
<p class=MsoNormal><span lang=EN-US>The prognosis is poor for patients with AKI
in end stage kidney disease. This is an emergency and should lead to an<i> </i>urgent
referral of the patient to EFSTH following stabilisation, or conservative
management.</span></p>
<h3><span lang=EN-US>Anaemia</span></h3>
<p class=MsoNormal><span lang=EN-US>Iron replacement therapy is often effective
in anaemia of CKD. Erythropoietin may be needed in later stages.</span></p>
<h3><span lang=EN-US>Hypocalcaemia</span></h3>
<p class=MsoNormal><span lang=EN-US>Hypocalcaemia in patients with GFR &lt; 30
ml/min/1.73m<sup>2</sup> (stage G4 or G5) should be treated with cholecalciferol
as  hypocalcaemia results from Vitamin D deficiency.</span></p>
<h2><span lang=EN-US>Referral to EFSTH</span></h2>
<p class=MsoNormal><span lang=EN-US>Referral criteria include:</span></p>
<p class=MsoListParagraphCxSpFirst style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>GFR &lt; 60 ml/min/1.73m<sup>2</sup> AND
visible/persistent invisible haematuria </span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>GFR &lt; 45 ml/min/1.73m<sup>2</sup> with at
least 1+ proteinuria</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>GFR &lt; 30 ml/min/1.73m<sup>2</sup> (category
G4/G5)</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Sustained decrease in GFR of &gt; 15
ml/min/1.73m<sup>2</sup> over 12 months</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Sustained decrease of 25% in GFR and a change in
GFR category within 12 months</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Suspected genetic or rare causes of CKD</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Suspected renal artery stenosis</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>AKI with a background of End Stage CKD
(emergency)</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Uraemic features such as gastritis,
pericarditis, pleuritis and encephalopathy</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>CKD and Hypertension refractory to treatment
with 4 or more antihypertensive agents</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Nephrolithiasis</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Persistent abnormalities in serum potassium.</span></p>
<p class=MsoNormal><span lang=EN-US>Referral should be made to EFSTH
Nephrologist via the Accident and Emergency Department.</span></p>
<p class=MsoListParagraphCxSpFirst style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Stabilise medical conditions such as
hyperkalaemia, uraemic symptoms, acidosis and fluid overload before ambulance
transfer.</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If possible, address correspondence to EFSTH
renal physicians for referral and long-term management plan. </span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<div class="tableCont">
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
style='font-size:14.0pt'><img width=576 height=268 id="Picture 3"
src="ckd_image001.png"></span></b></p>
</div>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
lang=EN-US><br clear=all style='page-break-before:always'>
</span><b><span lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<br clear=ALL>
<h2><span lang=EN-US>Key Issues for Nursing care</span></h2>
<p class=MsoListParagraphCxSpFirst style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Monitoring of urine output is essential.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Daily review of fluid management.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Oral intake is encouraged.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Good skin care should be practiced in patients
with peripheral oedema.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Patient mobility and self-care should be
actively encouraged.</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Patients should continue to eat a balanced diet,
and certain foods containing high amounts of potassium, such as bananas should
be avoided.</span></p>
<h2><span lang=EN-US>References</span></h2>
<p class=MsoNormal><span lang=EN style='font-size:10.0pt;color:black'>Kerr M,
Bray B, Medcalf J et al. (2012) Estimating the financial cost of chronic kidney
disease to the NHS in England. Nephrology Dialysis Transplantation. 27 (Suppl.
3): iii73–80]</span></p>
<p class=MsoNormal><span lang=EN style='font-size:10.0pt;color:black'>National
Institute for Health and Care Excellence (2015) <i>Chronic kidney disease in
adults: assessment and management </i>Clinical guideline [CG182] (available at </span><span
lang=EN-US><a href="https://www.nice.org.uk/guidance/cg182%20accessed%201/11/18"><span
class=InternetLink><span lang=EN style='font-size:10.0pt;color:black'>https://www.nice.org.uk/guidance/cg182
accessed 1/11/18</span></span></a></span><span lang=EN style='font-size:10.0pt;
color:black'>)</span></p>
<p class=MsoNormal><span lang=EN style='font-size:10.0pt;color:black'>Kidney
disease improving global outcomes (KDIGO): 2012 Clinical Practice Guideline for
the Evaluation and Management of Chronic Kidney Disease. (available at </span><span
lang=EN-US><a
href="http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf"><span
class=InternetLink><span lang=EN style='font-size:10.0pt;color:black'>http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf</span></span></a></span><span
lang=EN style='font-size:10.0pt;color:black'> (accessed 1/11/18)</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;color:black'>Rule
AD, Larson TS, Bergstralh EJ, et al; Using serum creatinine to estimate glomerular
filtration rate: accuracy in good health and in chronic kidney disease. Ann
Intern Med. 2004 Dec 21;141(12):929-37. </span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;color:black'>Levey
AS et al; A new equation to estimate glomerular filtration rate. Ann Intern
Med. 2009 May 5;150(9):604-12.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;color:black'>Inker
LA et al; Estimating glomerular filtration rate from serum creatinine and
cystatin C. N Engl J Med. 2012 Jul 5;367(1):20-9. doi: 10.1056/NEJMoa1114248.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;color:black'>Boulware
LE, Jaar BG, Tarver-Carr ME et al. Screening for proteinuria in US adults: a
cost-effectiveness analysis. JAMA 2003; 290: 3101–3114.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;color:black'>White
SL, Yu R, Craig JC et al. Diagnostic accuracy of urine dipsticks for detection
of albuminuria in the general community. Am J Kidney Dis 2011; 58: 19–28.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;color:black'>Lamb
EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured?
Ann Clin Biochem 2009; 46: 205–217.</span></p>
<div class="tableCont">
  <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US style='color:black'>Written by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US style='color:black'>Name: Thomas Sammut</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-justify:inter-ideograph'><span lang=EN-US style='color:black'>Date:
  29 November 2018 </span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US style='color:black'>Reviewed by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US style='color:black'>Name: Fatai Akemokwe</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-justify:inter-ideograph'><span lang=EN-US style='color:black'>Date:
  04 February 2019 </span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US style='color:black'>Version:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US style='color:black'>Change history:</span></b></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US style='color:black'>Review due date:</span></b></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US style='color:black'>1.0</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US style='color:black'>New document</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US style='color:black'>31 May 2021</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US style='color:black'>Review Comments (<i>if applicable)</i></span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US style='color:black'>&nbsp;</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
</div>
</div><!-- /content -->
<div data-role="panel" data-position="right" data-display="overlay" data-position-fixed="true" data-theme="b" id="leftpanel1">
	<a href="#" data-rel="close" data-theme="b" class="ui-btn ui-corner-all ui-shadow ui-btn-a ui-icon-delete ui-btn-icon-notext ui-btn-right">Close</a>
  <h1>About this app</h1>
  <div>
    This app is designed to provide doctors and nurses with quick access to the clinical guidelines of the Clinical Services Department of the MRC Unit The Gambia at LSHTM. <br>Users will be notified of updates via departmental email. <br>For feedback or support, email fakemokwe@mrc.gm
  </div>
</div>
</div>
<div data-role="footer" data-tap-toggle="false" data-id="persistent-footer" data-position="fixed" data-theme="a">
  <a href="index.html" class="ui-btn ui-corner-all ui-btn-inline ui-mini footer-button-left ui-btn-icon-left ui-icon-home">Home</a>
  <a href="#" onclick="topFunction()" id="myBtn" class="ui-btn ui-corner-all ui-btn-inline ui-mini footer-button-right ui-btn-icon-right ui-icon-carat-u">Top</a>  
</div>
</body>
</html>
